Merkel Cell Carcinoma - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 157 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 7, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Merkel Cell Carcinoma Overview 7
Pipeline Products for Merkel Cell Carcinoma - Overview 8
Pipeline Products for Merkel Cell Carcinoma - Comparative Analysis 9
Merkel Cell Carcinoma - Therapeutics under Development by Companies 10
Merkel Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 11
Merkel Cell Carcinoma - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Merkel Cell Carcinoma - Products under Development by Companies 15
Merkel Cell Carcinoma - Products under Investigation by Universities/Institutes 16
Merkel Cell Carcinoma - Companies Involved in Therapeutics Development 17
Amgen Inc 17
Apcure SAS 18
BeiGene Ltd 19
Immune Design Corp 20
Merck & Co Inc 21
Merck KGaA 22
Millennium Pharmaceuticals Inc 23
NantKwest Inc 24
Novartis AG 25
OncoSec Medical Inc 26
Oncovir Inc 27
Ono Pharmaceutical Co Ltd 28
Merkel Cell Carcinoma - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
aNK Program - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
APC-001 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
avelumab - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
BGBA-317 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
DNA IL-12 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
EBC-46 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
G-100 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
nivolumab - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
pasireotide - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
pazopanib hydrochloride - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
pembrolizumab - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Poly-ICLC - Drug Profile 139
Product Description 139
Mechanism Of Action 139
R&D Progress 139
sapanisertib - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
talimogene laherparepvec - Drug Profile 145
Product Description 145
Mechanism Of Action 145
R&D Progress 145
Vaccine to Target WT1 for Oncology - Drug Profile 151
Product Description 151
Mechanism Of Action 151
R&D Progress 151
Merkel Cell Carcinoma - Product Development Milestones 152
Featured News & Press Releases 152
Nov 29, 2016: FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review 152
Nov 14, 2016: NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors 153
Oct 31, 2016: European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma 153
Sep 28, 2016: Merck to Present Data on Avelumab at ESMO 2016 154
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 156
Disclaimer 157

List of Tables

Number of Products under Development for Merkel Cell Carcinoma, H2 2016 8
Number of Products under Development for Merkel Cell Carcinoma - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Merkel Cell Carcinoma - Pipeline by Amgen Inc, H2 2016 17
Merkel Cell Carcinoma - Pipeline by Apcure SAS, H2 2016 18
Merkel Cell Carcinoma - Pipeline by BeiGene Ltd, H2 2016 19
Merkel Cell Carcinoma - Pipeline by Immune Design Corp, H2 2016 20
Merkel Cell Carcinoma - Pipeline by Merck & Co Inc, H2 2016 21
Merkel Cell Carcinoma - Pipeline by Merck KGaA, H2 2016 22
Merkel Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 23
Merkel Cell Carcinoma - Pipeline by NantKwest Inc, H2 2016 24
Merkel Cell Carcinoma - Pipeline by Novartis AG, H2 2016 25
Merkel Cell Carcinoma - Pipeline by OncoSec Medical Inc, H2 2016 26
Merkel Cell Carcinoma - Pipeline by Oncovir Inc, H2 2016 27
Merkel Cell Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 28
Assessment by Monotherapy Products, H2 2016 29
Number of Products by Stage and Target, H2 2016 31
Number of Products by Stage and Mechanism of Action, H2 2016 33
Number of Products by Stage and Route of Administration, H2 2016 35
Number of Products by Stage and Molecule Type, H2 2016 37